Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)
CNY 14.43
(0.42%)
CNY 14.43
(0.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 53.23 Million CNY | -69.15% |
| 2022 | 113.72 Million CNY | -16.61% |
| 2021 | 132.18 Million CNY | -23.23% |
| 2020 | 174.92 Million CNY | 8.62% |
| 2019 | 165.81 Million CNY | 34.77% |
| 2018 | 111.89 Million CNY | -2.43% |
| 2017 | 116.58 Million CNY | 29.02% |
| 2016 | 94.7 Million CNY | 56.93% |
| 2015 | 62.97 Million CNY | 38.49% |
| 2014 | 42.88 Million CNY | 47.75% |
| 2013 | 30.33 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.22 Million CNY | -85.03% |
| 2024 Q3 | 28.75 Million CNY | 354.81% |
| 2024 Q1 | 30.44 Million CNY | 153.26% |
| 2023 Q2 | 27.04 Million CNY | -30.21% |
| 2023 Q1 | 38.75 Million CNY | 191.74% |
| 2023 FY | - CNY | -69.15% |
| 2023 Q4 | -97.66 Million CNY | -582.27% |
| 2023 Q3 | 20.25 Million CNY | -25.12% |
| 2022 Q4 | -42.23 Million CNY | -187.57% |
| 2022 Q3 | 48.23 Million CNY | 18.08% |
| 2022 Q2 | 40.84 Million CNY | 67.31% |
| 2022 Q1 | 24.41 Million CNY | 370.54% |
| 2022 FY | - CNY | -16.61% |
| 2021 Q4 | -9.02 Million CNY | -122.74% |
| 2021 Q1 | 25.69 Million CNY | -52.05% |
| 2021 FY | - CNY | -23.23% |
| 2021 Q2 | 54.26 Million CNY | 111.19% |
| 2021 Q3 | 39.68 Million CNY | -26.88% |
| 2020 Q2 | 54.56 Million CNY | 187.95% |
| 2020 Q1 | 18.95 Million CNY | -65.03% |
| 2020 Q3 | 39.95 Million CNY | -26.78% |
| 2020 Q4 | 53.58 Million CNY | 34.13% |
| 2020 FY | - CNY | 8.62% |
| 2019 Q4 | 54.18 Million CNY | 83.52% |
| 2019 FY | - CNY | 34.77% |
| 2019 Q3 | 29.52 Million CNY | -16.26% |
| 2019 Q2 | 35.25 Million CNY | -0.0% |
| 2019 Q1 | 35.25 Million CNY | 0.0% |
| 2018 FY | - CNY | -2.43% |
| 2017 FY | - CNY | 29.02% |
| 2016 FY | - CNY | 56.93% |
| 2015 FY | - CNY | 38.49% |
| 2014 FY | - CNY | 47.75% |
| 2013 FY | - CNY | 0.0% |